S100A8 and breast cancer: MDSC-derived S100A8/A9 significantly elevates the release of human matrix metalloproteinases from cancer cells to catabolize the ECM (Hu et al., 2021), increasing the invasiveness of proliferative BC tumors (Brisson et al., 2015) and causing widespread recurrence and metastasis (Di Martino et al., 2022).